AstraZeneca/Sanofi’s Nirsevimab Nears US FDA Approval After Overwhelmingly Positive Adcomm

 
• By Derrick Gingery
  
FDA AMDAC meeting screenshot
Advisory committee members voted that the benefits outweigh the risks of the proposed RSV prevention treatment nirsevimab. • Source: Screenshot
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers